Health care industry
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
Products of Hims & Hers displayed. Hims & Hers Shares of Hims & Hers Health tumbled more than 23% on Friday after the U.S. Food and Drug Administration announced that the shortage of semaglutide injection products has been resolved. Semaglutide is the active ingredient in Novo Nordisk’s blockbuster weight loss drugs Wegovy and diabetes treatment Ozempic. Those […]
Read More
Shortage of Novo Nordisk’s Wegovy and Ozempic drugs is resolved, FDA says
Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. Hollie Adams | Reuters The long-running U.S. shortage of Novo Nordisk‘s blockbuster weight loss injection Wegovy and diabetes treatment Ozempic is resolved after more than two years, the Food and Drug Administration said on Friday. The FDA’s decision will threaten the […]
Read More
Shortage of Novo’s Wegovy and Ozempic is resolved, FDA website shows
Weight loss syringes of the brands “Wegovy”, “Ozempic” and “Mounjaro” are sold at In der Achat Apotheke in Mitte, Germany. Picture Alliance | Picture Alliance | Getty Images A shortage of Danish drugmaker Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration’s website showed on […]
Read More
UnitedHealth’s rough stretch continues, with buyouts, a reported DOJ probe and a 23% drop in three months
FILE PHOTO: The logo of Down Jones Industrial Average stock market index listed company UnitedHealthcare is shown in Cypress, California April 13, 2016. Mike Blake | Reuters UnitedHealthcare is in hot water again as the insurance giant grapples with a reported government investigation of its Medicare billing practices, pursues employee buyouts and potential layoffs and […]
Read More
Eli Lilly aims to invest in ‘big problems hiding in plain sight’ using obesity windfall
Heart disease. Hearing loss. Addiction. Chronic pain. Alzheimer’s. ALS. These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big bets. These are the ideas that are “hiding in plain sight,” said Lilly Chief Scientific Officer Dan Skovronsky. They’re places where other pharmaceutical companies might not […]
Read More
From pills to new uses, here’s what Eli Lilly’s top scientist sees as the future of weight loss drugs
Dan Skovronsky knows what makes a good obesity drug. As chief scientific officer at Eli Lilly, he’s already done it once with the company’s weekly shot, Zepbound. He’s trying to do it again with a more convenient daily pill, then repeat the feat with a shot that could be even more powerful than Zepbound. And […]
Read More
Healthy Returns: Ozempic helps curb alcohol use in new study — and doctors are concerned about telehealth GLP-1s
Steve Christo | Corbis News | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk‘s blockbuster diabetes drug Ozempic may also help people drink less alcohol. That’s according to new government-funded research […]
Read More
UnitedHealthcare is offering buyouts to employees in benefits unit, could pursue layoffs, sources say
A general view outside the United Healthcare corporate headquarters on December 4, 2024 in Minnetonka, Minnesota. Stephen Maturen | Getty Images UnitedHealthcare is offering certain employees in its benefits operations unit the option to accept buyouts if they quit by March 3, following a tumultuous year for the insurance giant, CNBC has learned. Those who […]
Read More
AI health-care startup OpenEvidence raises funding from Sequoia at $1 billion valuation
Medical technology, AI technology is utilized by doctors for diagnosing increasing the accuracy of patient treatments. Medical research and development innovation technology to improve patient health. Pcess609 | Istock | Getty Images AI startup OpenEvidence is raising a fresh round of capital from Sequoia to scale its chatbot for doctors. The new $75 million cash […]
Read More
Hims & Hers to offer at-home blood draws and lab testing with new acquisition
Hims & Hers Health announced Wednesday it has acquired New Jersey-based at-home lab testing facility Trybe Labs. The deal will allow the telehealth company to offer at-home blood draws and more comprehensive pre-treatment testing to its users. “Access to richer data allows us to deepen the insights that providers can use on our platform to […]
Read More